Brian Shields discusses TROPION-Lung01 Clinical Trial and AI’s role in content curation

Brian Shields, Creator of KOL Pulse AI, posted the following on LinkedIn:

“One of the more interesting trials at the recent WCLC24 conference was the presentation of data on the TROPION-Lung01 Clinical Trial. This involved the study of DataDXD for advanced NSCLC after prior treatment vs the nearly 30-year-old gold standard docetaxel (AstraZeneca and Daiichi Sankyo US).

This trial provides a great perspective into the modern world of PR, social media, AI, FDA approvals, and Biomarkers. I used the KOL Pulse AI application to develop a long form tweet on TROPION-Lung01 with sourced content from KOL social media discussions.

So what’s the takeaway?

With AI, you can understand and develop content on very complicated topics with effective curation of the sourced data set. KOL tweets from ASCO24 and WCLC24 are a great example of this rich data set.

Check out the tweet on TROPION-Lung01.”

Source: Brian Shields/LinkedIn